electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic technology company dedicated to improving health and quality of life through innovative non-invasive bioelectronic technologies. The company's mission is to help patients globally who suffer from pain and chronic conditions by harnessing the power of non-invasive vagus nerve stimulation (nVNS), innovation, and technology to develop safe and clinically backed treatments. Its global headquarters are located in Rockaway, New Jersey, USA.

The company's key product portfolio includes gammaCore, a prescription handheld device cleared by the FDA for the acute and preventive treatment of primary headache disorders such as migraine and cluster headache. Additionally, electroCore offers Quell Fibromyalgia, a neurostimulator for chronic pain syndromes, and commercializes personal-use consumer products like Truvaga and TAC-STIM, which utilize nVNS technology for general wellness and human performance. electroCore operates across prescription medical devices, direct-to-consumer wellness, and government/military market segments, with a presence in the United States, the United Kingdom, Japan, and other international regions.

In recent news, electroCore reported record full-year 2025 net sales of $32.0 million, representing approximately 27% year-over-year growth. The company announced that CEO Dan Goldberger would retire on April 1, 2026, with Joshua Lev appointed as interim President and Michael Fox hired as Chief Operating Officer. Further demonstrating its innovation, electroCore's TAC-STIM product was named a national semifinalist in the National Safety Council 2026 Work to Zero Safety Innovation Challenge in April 2026, and the company expanded its intellectual property portfolio with new U.S. patents in early 2026.